Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== ParvOryx ====== The clinical development of ParvOryx started in Q3 2011. The Phase I/IIa trial is designed to treat patients with primary or recurrent glioblastoma multiforme using parvovirus H1. This trial is open-labeled and conducted at single center. Primary objectives of the trial are safety, maximum tolerated dose, viremia and virus shedding. Secondary objectives are efficacy, progression-free survival up to six months and overall survival. For more information see: Mode of action of parvovirus H1 and ClinicalTrials.gov parvoryx.txt Last modified: 2024/06/07 02:56by 127.0.0.1